Advanced Human Imaging Limited. Stock Price, News & Analysis

Advanced Health Intelligence Ltd (AHI) (symbol: AHI) is a digital health technology company in the information sector, classified under software publishers. According to company disclosures, AHI focuses on smartphone-delivered biometric health assessment, risk stratification, and digital triage capabilities that can be deployed at scale for healthcare providers, insurers, employers, and government agencies worldwide.

AHI is listed on both the ASX and NASDAQ. A Form 25 filed with the U.S. Securities and Exchange Commission in August 2025 shows that the company’s American Depositary Shares were removed from listing on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. This delisting relates to the ADS listing on Nasdaq and does not, by itself, describe the broader operational status of the underlying business.

Core technology and biometric health assessment

Company materials describe AHI as delivering health-tech innovation via a smartphone-based platform. Its technology has been developed to perform:

• Body dimension and composition assessment to help identify comorbidities associated with obesity, including diabetes risk estimates.
• Blood biomarker prediction, including estimates for HbA1C, HDL, LDL, and 10‑year mortality risk.
• Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
• On-device dermatological skin identification across hundreds of skin conditions and categories, including melanoma.
• Support for therapeutic and non‑therapeutic health coaching, assisting partners in delivering personalized programs to improve daily habits and build health literacy.

These componentized capabilities are combined in AHI’s Biometric Health Assessment (BHA), which the company describes as a multi-step process using BodyScan, FaceScan and finger-based photoplethysmogram (PPG). The BHA is designed to operate on a smartphone, using device sensors and proprietary algorithms to estimate health risks.

According to company descriptions, the BHA process can include:

• FaceScan to help determine blood pressure risk zones while collecting contextual data such as demographic information, daily activity intensity, chronic medication usage, and smoking status.
• PPG resting heart rate measurement, capturing resting heart rate in a guided posture.
• BodyScan body composition analysis, producing waist and hip circumference and body fat percentage.
• Cardiovascular fitness evaluation through an exertion test and heart rate recovery monitoring.

Following completion of the BHA, users receive a Health Risk Assessment (HRA) report. The company states that its algorithms, trained on smartphone sensor data and informed by peer‑reviewed medical protocols, can estimate additional measures related to human mortality and morbidity risk, including digital blood lipid biomarkers, inflammation markers, cardiorespiratory fitness, and HbA1C.

Digital triage and population-scale risk stratification

Across multiple press releases, AHI describes its mission as bringing biometrically derived triage and proactive health risk identification to large populations via smartphones. Its technology is presented as a way for partners to:

• Identify health risks across consumer or member populations.
• Stratify individuals into right‑care pathways for proactive health management.
• Support population health and preventive care initiatives, including early identification of chronic disease risks.

The company’s communications emphasize that its algorithms are built on research and risk classifications from organizations such as the World Health Organization, International Diabetes Federation and the U.S. Centers for Disease Control and Prevention, which AHI states it has digitized into a smartphone-delivered platform.

Key partner and market focus areas

AHI’s news releases outline collaborations and target markets for its biometric health assessment and related tools:

• Insurance and reinsurance: AHI has announced a letter of intent with Unisure Group, working with global reinsurer SCOR, to design and deploy a digital underwriting solution using the Biometric Health Assessment. The intent described is to digitize phenotypical biometric data and combine AHI’s digital blood biomarkers with actuarial and underwriting data for health and life insurance offerings.
• Digital health records and emerging markets: AHI signed a binding term sheet with Vietnam-based OneClinic to integrate its BHA into OneClinic’s interoperable electronic medical record and personal health record systems (OneEMR and OnePHR). The parties plan to conduct thousands of health assessments via mobile screening clinics as part of a funded research project prior to broader commercialization.
• Middle East collaborations: AHI has entered into agreements and collaborations with entities such as IntelliGen FZ‑LLC and Bin Farhood International Business Management Group L.L.C. These arrangements are described as focusing on deploying AHI’s technology to address chronic disease burdens and to support digital health and early intervention initiatives in the Middle East and North Africa region.
• Consumer engagement and wellness platforms: AHI’s biometric capabilities are being integrated into the rewards-based health platform of Bearn LLC. In one collaboration, Bearn and OnCore Innovations plan to use AHI scanning technology to provide golfers with insights into metabolic health while linking health improvements to financial rewards.

In addition, AHI has highlighted its selection as a finalist in Singapore’s Healthcare InnoMatch program, a Ministry of Health–linked initiative aimed at accelerating adoption of market-ready healthcare innovations for population health and aged care.

Technology domains and expertise

Across its disclosures, AHI attributes its platform to a team of subject matter experts in machine learning, artificial intelligence, computer vision, and medically trained data science. The company describes its work as digitizing scientific risk models and combining them with smartphone sensor data to produce health risk estimates across domains such as:

• Cardio‑respiratory risk.
• Body composition and obesity-related comorbidities.
• Estimated blood biomarkers and metabolic health.
• Mental health indicators, as part of broader risk categorization.
• Dermatological risk, through on-device skin condition identification.

AHI positions its technology as suitable for use by healthcare providers in both virtual and traditional care environments, and by insurers and employers seeking to support preventive care, health literacy, and chronic disease management among large groups.

Capital and listing considerations

In a funding-related announcement, AHI reported securing a convertible loan facility intended for working capital, with features such as a fixed conversion price, a defined maturity period, and shareholder approval requirements for any conversion into equity. The company’s board indicated that this structure was viewed as favorable compared with certain other capital-raising options, particularly in relation to potential dilution and timing.

Separately, a Form 25 filed in August 2025 by Nasdaq Stock Market LLC with the SEC documents the removal of AHI’s American Depositary Shares from listing and registration under Section 12(b). Investors researching the AHI stock should consider that this filing relates to trading venue status for the ADSs and consult up-to-date market data for current trading arrangements, if any.

Use cases and potential applications

Based on company statements, AHI’s biometric and digital triage tools are being positioned for use in:

• Insurance underwriting and risk scoring, where digital phenotypical data and estimated biomarkers can inform coverage design and pricing methodologies.
• Population screening programs, such as mobile clinics and large-scale chronic disease risk assessments in markets like Vietnam.
• Government and public health initiatives, including programs focused on aging populations and preventive care.
• Employer and wellness programs, where biometric risk assessments can be combined with coaching and incentives to encourage healthier behaviors.

These use cases are described by the company as leveraging smartphones to extend access to risk identification and health insights beyond traditional clinical settings.

Company status and research considerations

For investors and researchers looking at AHI stock, it is important to distinguish between the company’s technology and commercial collaborations and its securities listing status. The available SEC filing explicitly confirms that AHI’s American Depositary Shares were removed from listing on Nasdaq via Form 25 in 2025. The news releases outline active technology development and partnerships across multiple regions and sectors but do not, by themselves, provide a complete picture of the company’s financial condition.

Anyone analyzing AHI may wish to review its historical and current filings (including Forms 20‑F, 6‑K and other disclosures), as well as local exchange announcements, to understand the evolution of its business model, capital structure, and listing arrangements over time.